Can I read Heparin/rivaroxaban: Major, non-major bleeding following off-label use and lack of efficacy: 13 case reports on EtoBox?

Heparin/rivaroxaban: Major, non-major bleeding following off-label use and lack of efficacy: 13 case reports is a Medicine article available to read on EtoBox.

What is Heparin/rivaroxaban: Major, non-major bleeding following off-label use and lack of efficacy: 13 case reports about?

S Heparin/rivaroxaban Major, non-major bleeding following off-label use and lack of efficacy: 13 case reports In a prospective cohort study of 29 adolescents with acute venous thromboembolism (VTE) patients treated with oral rivaroxaban were enrolled into the Dresden NOAC Registry, 13 patients including 3 boys and 10 girls aged 14-17 years were described, who developed major or non-major bleeding during off-label (in unapproved age group) treatment with rivaroxaban for pulmonary embolism, deep vein thrombosis (DVT), distal DVT or proximal DVT. One of them exhibited lack of efficacy with heparin, while being treated as an anticoagulant therapy [dosages, durations of treatments to reaction onsets and outcomes not stated; not all routes stated].The adolescent patients, who had pulmonary embolism and deep vein thrombosis (DVT) (n=3), distal DVT (n=2) or proximal DVT (n=10) received off-label (in unapproved age group) treatment with oral rivaroxaban. The patient's family history was remarkable for acute venous thromboembolism. The patient's previous treatment included unspecified low molecular weight heparins. Some patient's family history was significant for acute venous thromboembolis

Who reads Heparin/rivaroxaban: Major, non-major bleeding following off-label use and lack of efficacy: 13 case reports?

Publisher

Springer Science and Business Media LLC

Published

2023

Language

EN

Field

Medicine (Health Sciences)